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We extend a physiologically-based lattice model for the transport and metabolism of
drugs in the liver lobule (liver functional unit) to consider structural and spatial
variability. We compare predicted drug concentration levels observed exiting the
lobule with their detailed distribution inside the lobule, and indicate the role that
structural variation has on these results. Liver zonation and its role on drug
metabolism represent another aspect of structural inhomogeneity that we consider
here. Since various liver diseases can be thought to produce such structural
variations, our analysis gives insight into the role of disease on liver function and
performance. These conclusions are based on the dominant role of convection in
well-vascularized tissue with a given structure.Background
The liver is the major organ responsible for the metabolism and detoxification of
drugs. Within the liver, it is the hepatocytes which express a high level of drug-
metabolizing enzymes and are primarily responsible for liver drug disposition. Drug
access to hepatocytes is governed by transport processes in the well-vascularized liver
tissue, and structural variability can obviously impact such transport. In this paper, we
extend our physiologically-based lattice model for the transport and metabolism of
drugs in the functional unit of the liver [1] (paper I) to consider spatial and structural
variability and its impact on hepatic drug metabolism.
The liver lobule and drug kinetics
Functional unit as a regular lattice model
The functional unit of the liver is termed the liver lobule [2] and is the smallest struc-
tural unit with complete hepatic functionality. Although various definitions of this unit
have been proposed, we have chosen a symmetry element connecting the portal (arter-
ial) tract with hepatic venules. In our first paper, we defined a base-case regular lattice
structural model and explored the dynamics of competing convective, diffusive, and re-
active processes acting on an injected drug (paclitaxol). Such simulations had the use-
ful consequence of relating drug concentration levels found exiting the lobule to their
detailed spatial distribution within the lobule, caused by competing processes. Tables
one to four in our first paper detail the parameters chosen for our regular lattice model© 2013 Rezania et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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obtained when some of these assumptions on lobule structure are relaxed, as discussed
in this current paper.Structural variability
Structural variability of lobule units is expected to be the rule, even among the approxi-
mately 1500 lobules that make up the liver of one healthy human. Teutsch and col-
leagues [4] illustrate this aspect morphologically.
Diseased states can be expected to add a spectrum of additionally variability. The
health of the liver can be compromised by viruses, hereditary diseases, and toxins such
as alcohol [5]. Damage or death of the hepatocytes leads to inflammation of the liver,
called hepatitis. Although zones of necrosis can form when adjacent cells die, this dam-
age is to some extent reversible, since the liver has the ability to regenerate. Thus hepa-
titis is typically characterized by waves of cell death and regeneration, leading to a
mixture of necrotic areas and nodules of new hepatocytes. Because the architecture of
the liver is often compromised, some cells may not receive normal levels of blood sup-
ply. Furthermore, as inflammation progresses, fibrous tissue may replace the normal
hepatocytes, resulting in the irreversible condition of cirrhosis. The damage can be
compounded because the formation of necrotic zones increases the resistance to blood
flow, and intra-hepatic shunts can occur in which blood vessels begin to bypass the
liver altogether. Therefore, although the liver has the capacity to withstand and even
correct a lot of damage, its ability to transport, absorb, and metabolize important nutri-
ents and drug molecules can be compromised.
A Base case model, of necessity, required numerous assumptions on an appropriate
idealization of the liver lobule structure. In our analysis, we will utilize the concept of a
random permeability lattice to capture small vascular irregularities in healthy livers,
and the more extreme effects of hypertension sustained due to hepatitis. Damage and
scarring occurring with cirrhosis will be treated within the framework of percolation
theory, such that the architecture of the liver is physically changed.Zonation and elimination kinetics
Zonation is a well-known feature of many metabolic processes occurring in the liver
lobule [6], including carbohydrate [7] and nitrogen [8] metabolism, such that some pro-
cesses are up-regulated near the periportal zone while others are up-regulated near the
perivenal side of the lobule. Drug metabolism and drug metabolizing enzymes also
show similar zonation features [9]. Our focus will be on the distribution of the cyto-
chrome P450 (CYP) enzyme in particular.
Zonation has been attributed primarily to non-uniform distribution of O2 across the
lobule [10], with the periportal zone experiencing relatively high concentrations of O2
while the perivenal zones see near hypoxic levels of O2. The distribution of other fac-
tors (e.g. growth factors) has also been shown to play a role. Indeed, injection of spe-
cific xenobiotic factors has been utilized to alter zoned enzyme expression levels
[11-13]. A future application of our model might be to track O2 distribution and me-
tabolism across the lobule. Here, for such a small molecule, molecular diffusion can be
expected to play a dominant role.
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lized product) is viewed as a single-step saturable process following Michaelis-Menten
kinetics [1].
Model and methods
The flow equations describing reactive-convective-diffusive flow in the liver lobule re-
main unchanged from our first paper. Figures 1a, b illustrate the network structure of
our Base case model from this paper. Here we focus on spatial variability in the flow
and reactive parameters.
MATLAB [14] was used to generate multiple realizations of spatial sinusoid perme-
ability variations drawn from a selected sinusoid permeability distribution function
(uniform, normal, or log-normal). We are interested in the sensitivity to the spread (i.e.
variation) of the distribution of this function, and we will use the term “Random Lat-
tice” to signify our studies in this portion of the work.
Specifically, random permeabilities between [a, b] (=Ksin [1-σ, 1 + σ] in our case) was
produced by the uniform random generator in MATLAB. Every representation is cre-
ated independently, multiplied by the sinusoidal permeability Ksin and then averaged
over the number of representations. Based on the central limit theorem, the average
value over the sample size N approaches the mean value (a + b)/2 (=Ksin in our case)
with standard deviation ~ 1/N1/2( ~ σ /N1/2 in our case). This means the mean value is
independent of σ. Permeability of tissue sites was set to constant Ktis = 7.35e-2 μm
2
after the sinusoidal permeability was set and averaged over the number of
representations.
Figures 2a-d show the histogram of permeability values for hepatocyte tissue and si-
nusoids with Ksin = 1.125 μm
2 and σ = 0.75 for 1, 10, 100 and 1000 realizations, respect-
ively. The first peak represents a permeability of tissue value Ktis = 7.35e-2 μm
2. As
expected, uniform distributed numbers tend toward the mean value. After N = 1000
sampling, only two peaks are left, one for the tissue and one for the sinusoids, similar
to the fixed tissue-sinusoid permeability case.
Multiple realizations of sinusoidal connectivity and degree of “disconnectiveness”
were also generated in a similar manner. Here, the approach to a percolation limit was
used to model blockage of flow. Lattices constructed in this manner are termed “Perco-
lation Lattices”. For this case, a random number between [0, 1] was assigned to each
site, Xi. Then by comparing the value at each site with a given percolation probability
Pc, the value of that site will change as follows:
Xi ¼ Ksin if Xi <¼ Pc⋅
Xi ¼ 0 if Xi >¼ Pc⋅
All Xi values were stored in a separate matrix for averaging purpose. Then a
new set random number was chosen for each site and the above procedure was
repeated up to desired number of samples. At the end, an averaged value found
over all representations was calculated for each site. The permeability of tissue
sites were again set to the constant 7.35e-2 μm2 and the permeability of corner si-
nusoidal sites set to Ksin.
Figure 1 (a) Schematic diagram of a cross section of hepatic parenchyma consisting of hexagonal
lobules, and the portal and hepatic veins. The lobule contains liver cells called hepatocytes and blood
vessels called sinusoids. The segment represents a typical area studied in this paper. (b) Homogeneous
lattice (segmented area). The high porosity bands represent sinusoids and the lower porosity regions
represent tissue containing hepatocytes. The Base case lattice as shown here has tissue porosity 0.2382. The
ideal case lattice (not shown) has tissue porosity 0.4764. The extracellular matrix (ECM) case lattice (not
shown) has tissue porosity 0.1191.
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Ksin = 1.125 μm
2 and Pc = 0.7 for 1, 10, 100 and 1000 realizations, respectively. The first
peak represents a permeability of tissue value of Ktis = 7.35e-2 μm
2. As expected, the
top panel is just for one representation that values are only 7.35e-2 μm2 or 1.125 μm2.
Adding more representations and averaging over them produces a second peak close to
the Pc value (here 0.7). This is true for any value of Pc. As a result, the fixed and aver-
aged random cases are similar to the extreme case of percolation with Pc = 1. The third
peak appearing in Figure 3 has value close to Pc Ksin.
Zonation effects in the lobule have been treated here by simply varying the spatial ex-
pression of the active CYP enzyme. Thus hepactocytes are assumed to be located
throughout the lobule tissue as in the Base case model, but the expression of CYP is as-
sumed to be regionally-biased at three levels (zero-, mid-, and full-expression). Two ex-
tremes are explored, with the zero expression zone located upstream (i.e. surrounding
the arteriole injection site) or downstream (i.e. surrounding the venuole production
Figure 2 Random lattice histogram of permeability values for tissue with a fixed sinusoidal values
of Ksin =1.125 μm2 and σ = 0.75. (a) N = 1 realization, (b) N = 10 realizations, (c) N = 100 realizations, and
(d) N = 1000 realizations. The horizontal axis is in μm2.
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the lobule.
The simulations were performed using the STARS advanced process simulator [15]
designed by the Computer Modelling Group (CMG) Ltd. in Calgary, Alberta, to model
the flow and reactions of multiphase, multicomponent fluids through porous media
[16,17]. Specific biomedical applications of STARS include modeling reactive flow pro-
cesses in cortical bone [18-21] and in the intervertabral disk [22].Results
Tissue permeability sensitivities on drug transport
Table 1 of the first paper proposed three levels of tissue porosity and permeability,
based on a theoretical model of flow and the Carmen-Kozeny equation. The Base case
model used the intermediate level for these parameters. Although not shown, we note
that the steady state flow rate is basically independent of the tissue permeability level
(Ideal, Base, or ECM) as the overall flow is determined primarily by the connected si-
nusoidal permeability value, which is the same in all three cases.
Figure 4 compares the produced paclitaxol drug profiles versus time for all three
tissue permeability levels, with and without additional diffusive transport, respectively.
Figure 3 Percolation lattice histogram of permeability values for tissue with a fixed sinusoidal
values of Ksin =1.125 μm2 and Pc = 0.7. (a) N = 1 realization, (b) N = 10 realizations, (c) N = 100
realizations, (d) N = 1000 realizations. The horizontal axis is in μm2.
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molecule. Paralleling the results in our first paper, the “no diffusion” runs (Figure 4b)
are much more responsive to structural changes than the “diffusion” runs (Figure 4a).
Diffusion as a process appears to smooth out the structural changes caused by perme-
ability variations, which is a convective effect. When interpreting these results, small-
sized drugs may be represented by the diffusive case, while large sized drugs can be
viewed as non-diffusive.
As the component (PAC/PAC-OH) spatial distributions for the flows with diffusion
do not vary significantly from those found in the first paper for the Base case tissue
permeability (Figure 5 in Paper I), here we discuss only the effect of tissue permeability
for reactive flows without diffusion. Figures 6a-f show both PAC and PAC-OH distribu-
tions in the Ideal permeability tissue model at 0.01, 0.14 and 0.5 min, respectively.
Compared to the Base case runs of the first paper, increasing the tissue permeability to
values comparable with the sinusoid permeability levels results in early time conversion
of PAC to PAC-OH and an almost uniform distribution of PAC-OH throughout the
lobule tissue at later times. In contrast, the more reduced tissue permeability for ECM
case results in a much lower and delayed PAC-OH metabolite appearance in the
tissue and almost negligible concentration levels in the sinusoids. This is shown in
Figures 7a-f for the same three time levels.
Table 1 Geometric average ranking of random permeability lattices












Base Case 2.44415e-6 2.4415e-6
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Effects of sinusoidal permeability on paclitaxol drug transport can be explored in the
same way as those of tissue permeability presented in the above section. Specifically,
representative upper and lower sinusoid permeability values could be selected around
the Base case value (Ksin = 1.125 μm
2), and their effects on drug transport could be pre-
dicted. Such an approach could also illustrate the effects of angio-sensitive molecules
causing uniform vascular restriction or dilation of sinusoidal pathways.
However, here we examine an alternate, more powerful and representative analysis of
sinusoid variability by creating various realizations from an appropriate sinusoid per-
meability distribution function, as described in the “Methods” section above. Figure 5
illustrates the different production behaviours produced by 11 realizations drawn from
a uniform sinusoid permeability distribution with a wide spread (σ = 1) of permeabil-
ities. Figure 5a demonstrates the range of lobule flow rates generated from these per-
meability distributions produced with a fixed fluid pressure difference across the lobule
Δp, while Figure 5b shows the corresponding paxlitaxol production history for each
representation. These figures demonstrate that higher flow rates generate earlier
paclitaxol production. This method also allows an assessment of the spread of expected
behavior by focusing on the 10%, 50%, and 90% cases. For the 11 realizations studiedFigure 4 Reactive (6e-3 min-1) PAC and PAC-OH drug propagation across the lobule, comparing
Base, Ideal, and ECM cases (a) with diffusion and (b) without diffusion.
Figure 5 (a) Water production rates, and (b) Non-reactive PAC production profiles for 11
realizations of random permeability lattice.
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show the permeability distribution profiles generated by our algorithm for these
three cases.
Figures 9a-c show non-reactive PAC distributions across the random permeability
lobule in the 10% (Try11) tissue realization at 0.01, 0.14 and 0.5 min, respectively, as-
suming no diffusive contribution to drug flows. This structural variation results in a de-
layed propagation of the drug across the lobule. In contrast, the increased effectiveFigure 6 Reactive (6e-3 min-1) PAC and PAC-OH profiles across the lobule with no diffusion effects
for Ideal case metabolism. PAC at (a) 0.01 min, (b) 0.14 min and (c) 0.50 min; PAC-OH at (d) 0.01 min, (e)
0.14 min and (f) 0.50 min. Color bar is in molfrac.
Figure 7 Reactive (6e-3 min-1) PAC and PAC-OH profiles across the lobule with no diffusion effects
for ECM case metabolism. PAC at (a) 0.01 min, (b) 0.14 min and (c) 0.50 min; PAC-OH at (d) 0.01 min, (e)
0.14 min and (f) 0.50 min. Color bar is in molfrac.
Rezania et al. Theoretical Biology and Medical Modelling 2013, 10:53 Page 9 of 20
http://www.tbiomed.com/content/10/1/53permeability of the 90% (Try4) tissue realization results in a much faster propagation.
This is shown in Figures 9d-f for the same three times. The 50% (Try 2) tissue
realization results in drug profiles across the lobule visually similar to the 90%
realization (not shown explicitly).
The above correlation between observed flow rates and expected paclitaxol pro-
duction behavior would prove extremely useful in ranking a large number (e.g.
1000) of realizations in terms of extreme behavior, as then only selected simulations
need be run to assess paclitaxol production response. We first explored an analytic
calculation for effective network permeability, which generated the observed steady
state flow rates in Figure 5, via an effective Darcy’s law calculation for a specified
Δp as follows:
Qchs ¼ F Keff Δp: ð1Þ
Here, F is a constant network geometric factor that assumes a constant viscos-
ity. For each realization, the effective network permeability can be estimated by
a geometric average of all sinusoid and tissue values in a given realization [23]
as follows:
ln Keff
  ¼ ∑Ni¼1 ln Kið ÞN : ð2Þ
A more general analytic averaging technique, termed power law averaging [24], can
also be attempted as:Figure 8 Generated permeability distribution for (a) 10% (Try11) case, (b) 50% (Try2) case and (c)
90% (Try4) case. Color bar is in μm2.
Figure 9 Non-reactive PAC profile across the lobule for 10% (Try11) case at (a) 0.01 min, (b)
0.14 min, and (c) 0.50 min and for 90% (Try4) case at (d) 0.01 min, (e) 0.14 min, and (f) 0.50 min. No
diffusion effect is considered. Color bar is in molfrac.
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Here the power “w” is a best fit parameter. This equation reduces to both arithmetic
and harmonic averages when the power “w” is 1 or −1 and becomes the geometric aver-
age when “w” is 0.
Finally, an effective permeability calculation that is possibly more correct but less effi-
cient can be generated using the “Effective Medium Theory” [25,26], given in 2D as:
Kwef f ¼ ∑Ni¼1
Kef f −Ki
Kef f þ Ki
 
: ð4Þ
This requires a root finding method, such as Newton’s method, to find the appropri-
ate answer. Newton’s method requires an initial estimate, appropriately chosen here as
the geometric average. Here, we investigated both the geometric and power law aver-
aging techniques, but with limited success.
As an illustration, Table 1 summarizes the geometric mean ranking of the 11 realiza-
tions used to generate the drug production responses of Figure 5. Table 1 additionally
quotes the flow rate obtained from our Base case (constant sinusoid permeability)
model in our first paper. This rate is significantly higher than the flows predicted from
any realization, even though individual permeability values were drawn symmetrically
from a distribution around the same average permeability. This illustrates that flow
paths within the lobule are at least partly in series, especially because of the diverging/
converging flow geometry of the model, and hence a harmonic component of flow re-
sistances can be expected (i.e. any lower permeability elements will tend to impart an
overall higher resistance to flow).
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this approach, we simulated one timestep (with a value large enough to represent
steady flow-1.0e-4 min or larger, see Figure 5) of a non-reactive case for each
realization. Our (fully implicit) numerical method is extremely stable to such large
timesteps and allows the calculation. This would represent one fixed time point for
each realization from Figure 5, for ranking purposes.
Rather than the 11 realizations used here for practicality, a more statistically consistent
sampling set would include, for example, 101 or 1001 realizations. Utilizing the same meth-
odology of ranking realizations, the 10%, 50%, and 90% cases can again be selected for fur-
ther detailed analysis. This is the recommended method for analyzing statistical realizations.Sinusoid percolation connectivity sensitivities on drug transport
More extreme disturbances in lobule flow conductivity can occur as connectivity is
complete (i.e. flow paths are connected). This may be expected to occur with more se-
vere liver damage and disease, such as hepatitis and increased fibrosis. Mathematically,
such instances can be appropriately analyzed via percolation theory, with extreme ef-
fects seen as the percolation limit is reached.
Figure 10 illustrates the change in flow and non-reactive drug propagation as the perco-
lation value is decreased from Pc = 1 on the Base case lattice. One sees a trend of decreas-
ing flow and later drug production as the Pc value is reduced. Each curve represents an
average of 100 realizations at a specific percolation value. These realizations were gener-
ated as described in the Methods section above. Further analysis of percolation behavior
at higher Pc values could be done as with the random permeability treatments; various re-
alizations for a given Pc level could be ranked, and single realizations corresponding to
10%, 50%, and 90% cumulative probability could be assessed dynamically. However, as the
Pc level is decreased, the use of geometric mean or effective permeability methods be-
comes less reliable. As the percolation limit is approached (Pc = 0.5 for a 2D lattice), the
average flow decreases to zero, and each realization can fluctuate wildly in predicted flow.
Figure 11a shows one realization of a percolation grid at Pc = 0.55. The corresponding
flow across this lattice is shown in Figure 11b. It is obvious that the steady state flow
rate is 100 times smaller than the Base case level, as is the time to reach steady state.
Figure 11c also illustrates the steady state flow velocity distribution across the lobule,
showing the many “dead” regions of flow.Figure 10 (a) Water flow rates and (b) PAC production rates at various percolation levels.
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tice can still be expressed as a solution of the convective-dispersion equation with an
effective dispersion coefficient, given as





Here, P is the dimensionless Peclet number, expressed as convective flow velocity
times length divided by the dispersion coefficient, while tR is the dimensionless time,
defined as time divided by the time required to get a dimensionless concentration CR =
0.5. It should be emphasized that the Sauty solution is for one-dimensional flow while
the real flow network here is two-dimensional with the possibility of internal cross
flows. For our network, the length of interest is the diagonal distance of 0.106 cm, and
the injected concentration is 1.8e-8 (mole fraction), implying a half concentration of
9.0e-9. Fitting the profile should allow estimates of the convective velocity and the ef-
fective dispersion for each case.
Table 2 summarizes the best fit results (from MATLAB) to such a profile for four cases–
our Base case network model with and without diffusion (see Figure 4 of Paper I), and the
percolation realization, also with and without diffusion. Generally, and following the ana-
lysis of Levitt [27], one should expect increased effective dispersion coefficients by adding
molecular diffusion to the “network dispersion” of the regular lattice and even more “net-
work dispersion” of the percolation lattice. Two calculations of effective dispersion coeffi-
cients from the fit value of the number are given. The first column uses the Base case flow
velocity for all calculations. Conversely, the second effective dispersion column recognizes
the reduced flow velocities occurring in the percolation network and adjusts the effectiveFigure 11 (a) One realization of a percolation grid at Pc = 0.55 (color bar is in μm
2), (b) injection and
production flow rates across one realization of the percolation grid (Pc = 0.55) with or without
diffusion and no reaction and (c) total flow velocity profile in cm/min across one realization of the
percolation grid (Pc = 0.55).
Table 2 Production profile fit to sauty [3] analytic convection-diffusion profile
Chalf tR P P
-1 Keff Keff_rs χ
2
Reg_nodiff 8.99e-9 0.2194 min 7.656 0.1306 1.306e-3 1.306e-3 1.83e-9
Reg_diff 9.00e-9 0.2228 min 6.503 0.1538 1.538e-3 1.538e-3 1.90e-9
Perc_nodiff 8.56e-9 8.7990 min 4.069 0.2458 2.548e-3 6.370e-5 66.2e-9
Perc_diff 9.02e-9 18.390 min 3.609 0.2771 2.771e-3 6.928e-5 1.11e-9
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dispersion coefficients for the four cases in Table 2 can be rationalized.
Figures 12a, b show the values for the percolation realization, with and without diffu-
sion. For non-reactive flow, percolation effects are seen to significantly reduce drug
transit times across the lobule, while generating a “structure-induced” increased effect-
ive dispersion coefficient for the produced drug profile. Also, while the matches to the
Sauty theoretical profile are excellent for the percolation case with diffusion (and for
the regular lattice Base case with and without diffusion), the no-diffusion percolation
case fit is poor. Although somewhat unclear from Figure 12b (MATLAB is attempting
a “best-fit” to the Sauty profile), this simulated case actually shows a long-time devi-
ation from the simple Sauty profile as the produced concentration approaches the
injected value. This can be attributed to slowly diffusing concentrations from partially
blocked areas inside the network as the outlet concentration eventually sweeps these
areas. Although we did not attempt equivalent fitting of our production profiles from
our random permeability realizations to the Sauty profiles, we expect that smaller ran-
dom deviations from our Base case model will also produce excellent “Sauty profile”
fits, while random realizations with more extreme distributions may not.
Next, we investigated reactive (metabolite-generating) processes on a percolation lob-
ule. Figure 13 shows reactive PAC and PAC-OH production profiles for this realization,
at two metabolic rates. With diffusion, PAC-OH is produced at both reaction rates, but
at different levels (Figure 13a), while without diffusion, only extremely high reaction
rates will produce PAC-OH (Figure 13b).
Reactive PAC and PAC-OH profiles across the percolation lobule are shown in
Figures 14 and 15. Here again we consider the case neglecting diffusive flow contribu-
tions to drug transport. The specified reaction rate in Figures 14a-f corresponds to the
Base case rate of our first paper. Here the PAC profiles follow directly the percolation
paths through the lobule, while PAC-OH is generated only in the tissue directlyFigure 12 Production profile fit to Sauty [3] analytic convection-diffusion profile for (a) percolation
example with diffusion, and (b) percolation example without diffusion.
Figure 13 Reactive PAC-OH profiles across the percolation lobule (Pc = 0.55) (a) with diffusion
effects and two metabolic rates, and (b) with no diffusion effects and various metabolic rates.
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distribution are even more extreme, as illustrated in Figures 15a-f.
Zonation and effects on drug elimination
Two zonation cases were analyzed: the upstream (normal) case, where CYP expression
is active primarily near the drug inlet zone, and the downstream (reversed) case, where
CYP expression is active primarily near the drug outlet zone. Typically, CYP expression
is expected to follow the latter case, but both are analyzed for comparison.
For each case, two scenarios were envisioned, an averaged (minor) difference in CYP
activity in the three zones, and an extreme scenario with larger differences in CYP
activity between the three zones (one of which has zero CYP activity, either upstream
or downstream). Table 3 lists relative CYP levels for each case. Figures 16a-b lists the
assumed CYP expression levels for the two extreme cases.Figure 14 Reactive (6e-6 min-1) PAC profile across the percolation lobule (Pc = 0.55) (a) at 2 min, (b)
at 28 min and (c) at 100 min with no diffusion effect. Reactive (6e-6 min-1) PAC-OH profile across the
percolation lobule (Pc = 0.55) (d) at 2 min, (e) at 28 min and (f) at 100 min with no diffusion effect. Color
bar is in molfrac.
Figure 15 Reactive (6e-9 min-1) PAC profile across the percolation lobule (Pc = 0.55) (a) at 2 min, (b)
at 28 min and (c) at 100 min with no diffusion effect. Reactive (6e-9 min-1) PAC-OH profile across the
percolation lobule (Pc = 0.55) (d) at 2 min, (e) at 28 min and (f) at 100 min with no diffusion effect. Color
bar is in molfrac.
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PAC and PAC-OH production profiles with diffusion contributions to the flow.
Zonation (either averaged or extreme) is seen to have no effect on the production
behavior compared to the Base case (no zonation) behavior. Note also that only
PAC-OH is produced here. However, with the same (reversed) zonation patterns,
but assuming no diffusive contribution to the flow, mostly unmetabolized PAC is
produced, and some differences in production behavior are seen with zonation.
This is summarized in Figure 17b.
These observations do not imply that unchanging metabolite distributions are occur-
ring within the lobule itself, as a function of assumed zonation. Figures 18a-f illustrate
the PAC and PAC-OH distributions across the lobule at 0.01 min, 0.14 min, and
0.50 min, respectively, for the extreme reversed zonation case without diffusion. A def-
inite upstream effect of no CYP metabolite processing is seen, but the more downsteam
levels of CYP can counteract this lack of activity, at least with the reaction rate assumed
in these runs. These results should be compared with the Base case (no zonation) runs
presented in our first paper. PAC and PAC-OH profiles at the equivalent time points
for the same extreme reversed zonation model, but with diffusive flow, are not shown
explicitly.Table 3 Relative CYP levels in ideal zonation cases
Case Relative CYP Levels (Upstream/Middle/Downstream)
Average zonation 0.75/0.50/0.25 (U/M/D)
Extreme zonation 1.00/0.50/0.00 (U/M/D)
Average reverse zonation 0.25/0.50/0.75 (U/M/D)
Extreme reverse zonation 0.00/0.50/1.00 (U/M/D)
Figure 16 Relative CYP concentration for (a) “extreme zonation” case and (b) “extreme reversed
zonation” case.
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http://www.tbiomed.com/content/10/1/53The normal zonation case is considered next. Figure 19a compares reactive PAC and
PAC-OH production profiles with diffusion contributions to the flow. Zonation (either
averaged or extreme) is seen to have no effect on the production behavior compared to
the Base case (no zonation) behavior. Note also that only PAC-OH is produced here.
However, with the same (normal) zonation patterns, but assuming no diffusive contri-
bution to the flow, mostly unmetabolized PAC is produced, and some differences in
production behavior are seen with zonation. This is shown in Figure 19b.
Zonation again affects the different metabolite distributions within the lobule itself.
Figures 20a-f illustrate the PAC and PAC-OH distributions across the lobule at
0.01 min, 0.14 min, and 0.50 min, respectively, for the extreme normal zonation case
without diffusion. As discussed above, a definite upstream effect of no CYP metabolite
processing is seen, but the more downsteam levels of CYP can counteract this lack of
activity, at least with the reaction rate assumed in these runs. These results should be
also compared with the Base case (no zonation) runs presented in our first paper. PAC
and PAC-OH profiles at the equivalent time points for the same extreme normal zon-
ation model, but with diffusive flow are not shown explicitly.Figure 17 Reactive (6e-3 min-1) PAC and PAC-OH metabolite production for reversed zonation
cases (a) with diffusion and (b) without diffusion.
Figure 18 Reactive (6e-3 min-1) PAC and PAC-OH profiles across lobule for extreme reversed case
without diffusion. PAC at (a) 0.01 min, (b) 0.14 min and (c) 0.50 min; PAC-OH at (d) 0.01 min, (e) 0.14 min
and (f) 0.50 min. Color bar is in molfrac.
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http://www.tbiomed.com/content/10/1/53Fractal behaviour in the liver-an alternate perspective
Previously, to take into account organ heterogeneity and simulate enzyme kinetics in
disordered media, lattice models have been introduced by several investigators. Berry
[28] performed Monte Carlo simulations of a Michaelis-Menten reaction on a two-
dimensional lattice with a varying density of obstacles to simulate the barriers to diffu-
sion caused by biological membranes. He found that fractal kinetics resulted at high
obstacle concentrations. Kosmidis et. Al. [29] performed Monte Carlo simulations of a
Michaelis-Menten enzymatic reaction on a two-dimensional percolation lattice at crit-
icality. They found that fractal kinetics emerged at large times.
Previously [30], we developed a network model of the liver consisting of a square lat-
tice of vascular bonds connecting two types of sites that represent either sinusoids or
hepatocytes. Random walkers with a drift velocity explored the lattice and were re-
moved with a set probability from hepatocyte sites. To simulate different pathologicalFigure 19 Reactive (6e-3 min-1) PAC and PAC-OH metabolite production profiles for zonation cases
(a) with diffusion and (b) without diffusion.
Figure 20 Reactive (6e-3 min-1) PAC and PAC-OH profiles across lobule for extreme case without
diffusion. PAC at (a) 0.01 min, (b) 0.14 min and (c) 0.50 min; PAC-OH at (d) 0.01 min, (e) 0.14 min and (f)
0.50 min. Color bar is in molfrac.
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http://www.tbiomed.com/content/10/1/53states of the liver, random sinusoid or hepatocyte sites were removed. For a lattice with
regular geometry, it was found that the number of walkers decayed according to an ex-
ponential relationship. For a percolation lattice with a fraction p of the bonds removed,
the decay was found to be exponential for high trap concentrations but transitioned to
a stretched exponential at low trap concentrations.
These models are all basically random walk models (emphasizing diffusive flow), and
the lattices are abstract representations of the geometry of the space. Here we have cre-
ated network models that incorporate realistic anatomical and physiological properties
of the liver as well as emphasizing the consequent convective flow behavior of the well-
perfused liver lobule. Here the fractal behavior of the liver lobule results from flow
inhomogeneities.
Figure 21 illustrates the reactive flow behavior as a function of percolation value, based
on our percolation lattice models described earlier. Data analogous to Figure 10, but forFigure 21 Percolation Network effects on (a) Steady State Flow (b) Produced Steady State Reactive
PAC and PAC-OH without diffusion.
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http://www.tbiomed.com/content/10/1/53base case reactive flow parameters, were used to generate these plots. Figure 21a shows a
decreasing steady state flow pattern as the lattice percolation value is decreased to the 2D
percolation limit of 0.5. This is analogous to the percolation patterns on 2D lattices ob-
served many years ago by Kirkpatrick [25] (see his Figure 3). Here, Figure 21b illustrates
the role of percolation on steady state produced PAC and PAC-OH as a function of perco-
lation value, using the Base case reaction parameters. These illustrate the role of incom-
plete mixing on reactive behavior in a normally convective-dominated network, especially
as the percolation limit is approached (and where convection ceases to be so dominant).
At or below the percolation threshold of 0.5, no PAC or PAC-OH is produced.Conclusion
Together with our previous paper, this work presents a useful framework for analyzing the
coupled and competing flow processes (convection/diffusion/reaction) that determine drug
propagation and availability in a well-vascularized tissue such as a liver lobule. With our
numerical approach, we have addressed both multidimensional spatial aspects as well as
transient and steady state time behavior. In this paper, we have emphasized the impact of
structural variability (including enzyme zonation) on non-uniform spatial distributions of
drug and drug-metabolites occurring across the lobule. In particular, our non-dispersive
models are shown to be more sensitive to such structural variations. We have also illus-
trated several techniques to quantify and analyze the role of such spatial variability.
Our network models including dispersive effects often correspond to the “well-
stirred” compartment models [31], such that relatively uniform steady-state concentra-
tion levels occur throughout the lobule (if one ignores the smaller inlet mixing zone).
Conversely, simulations on our network models without explicit dispersive mixing
often correspond to modified “parallel tube” models [32], in which observed concentra-
tion profiles change along the length of the tubes (i.e. sinusoids). (Here our modified
tube network structure allows cross-sinusoidal flow as well).
Aging and liver cirrhosis have been found to effect the transfer of drugs and metabo-
lites from sinusoids to tissue, rather than directly effect the intrinsic metabolic process
of hepatocytes [33,34]. Recognizing that the dispersive mixing terms in our models
allow easy permeation across the sinusoid-tissue interface, as well as improved intracel-
lular transport, our calculated concentration profiles “with diffusion” can be viewed
as representative of healthy liver behavior, while our non-diffusive profiles can be
interpreted as representing aged or cirrhotic liver behavior.
A subsequent paper will expand this analysis to include sensitivities associated with
variations in realistic lobule structure obtained from lobule images, which could even
more realistically reflect extents of liver damage.
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